Researchers discovered that the knockdown of chemokine ligand 18 (CCL18) suppresses cell growth and migration in thyroid cancer, according to the results of a new study published in the Journal of Healthcare Engineering.

Thyroid cancer can be classified into papillary, anaplastic, follicular, and medullary thyroid cancer (MTC). Thyroid cancer has been attracting increasing attention from medical researchers due to its fast-growing incidence. Although there are multiple theories on the risk factors associated with thyroid cancer, many aspects of it are still poorly understood. 

Read more about MTC etiology  

Continue Reading

CCL18 is a chemokine that has been studied for its relationship with various diseases since its discovery in 1997. In recent years, its role in tumor development has been confirmed, leading to more studies being conducted on its role as a potential cancer biomarker.

CCL18 has been associated with most human cancers, including prostate cancer, pancreatic cancer, ovarian cancer, cutaneous T cell lymphoma, and gastric cancer. However, the role of CCL18 in thyroid cancer has not been fully explored.

Sun and colleagues hence decided to clarify the relationship between CCL18 and thyroid cancer, if any. To carry out their study, they collected 66 tissue samples from patients with thyroid cancer undergoing surgical resection at the Yantaishan Hospital in China. All the specimens received a pathological diagnosis.

Using these samples, the research team conducted studies on the expression of CCL18 in thyroid cancer tissues and cells, as well as the effects of silencing CCL18. The results demonstrated that there was an uptrend of CCL18 expression in thyroid cancer tissues and cells.

“Our findings indicated that CCL18 overexpression facilitated lymph node metastasis in patients with TC [thyroid cancer]. CCL18 silencing was found to inhibit cell migration, proliferation, and [epithelial-mesenchymal transition] progression in TC cells,” Sun et al wrote.

The results demonstrate that CCL18 participated in the progression of thyroid cancer, making it a potential therapeutic target for future research.


Sun C, Wang P, Gao T, Chi J. CCL18 knockdown suppresses cell growth and migration in thyroid cancer. J Healthc Eng. Published online January 25, 2022. doi:10.1155/2022/1548155